非小细胞肺癌罕见靶点靶向治疗最新研究进展

Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer

靶向治疗的快速发展,使非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗取得革命性突破。相较于放化疗,靶向治疗可显著提高NSCLC患者的5年生存率,改善其预后。靶向治疗针对的靶点除常见的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变基因外,我国肺癌人群中还存在诸多罕见靶点,如间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)、间质表皮转化因子(mesenchymal to epithelial transition factor,MET)、人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)等。近年来,针对这些罕见靶点的新型药物不断更新、相继进入临床使用,并取得了令人惊艳的疗效。本文对以ALK、MET、HER2为靶点的靶向治疗最新研究进展进行梳理和总结,以期为NSCLC的临床治疗提供借鉴。

The rapid development of targeted therapy has made a revolutionary breakthrough in the treatment of non-small cell lung cancer(NSCLC).Compared with radiotherapy and chemotherapy,targeted therapy can significantly increase the five-year survival rate and improve the prognosis of NSCLC patients.In addition to the common epidermal growth factor receptor(EGFR)mutation genes,there are many rare targets for targeted therapy in Chinese lung cancer population,such as anaplastic lymphoma kinase(ALK),mesenchymal to epithelial transition factor(MET),human epidermal growth factor receptor 2(HER2),etc.In recent years,newly developed medicines for these rare targets have been continuously updated and entered clinical use one after another and have achieved amazing effects.This paper reviews and summarizes the latest research progress of targeted therapy targeting ALK,MET and HER2,in order to provide a reference for the clinical treatment of NSCLC.